Opinion

Video

Comparing Trials Studying Treatment Intensification In mHSPC

A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, and LATITUDE while highlighting the nuanced differences in adverse effect profiles and tolerability among these agents.

Comparative Analysis With Other mHSPC Trials

Key Themes:

  • Comparison between ARANOTE and other intensification trials (ARCHES, TITAN, LATITUDE)
  • Differences in patient populations and trial design
  • Unique attributes of various androgen receptor pathway inhibitors

Expert Insights:

  • Dr Shore compared darolutamide's performance in ARANOTE to other agents: enzalutamide (ARCHES), apalutamide (TITAN), and abiraterone (LATITUDE).

While all agents demonstrated benefit when combined with androgen deprivation therapy, Dr Shore noted important differences in adverse effect profiles, tolerability, and patterns of adoption in clinical practice.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.